Breathe Well-being vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Gurugram India YC W20 digital therapeutics for diabetes/PCOD/thyroid/hypertension reversal serving 150M Indian chronic disease patients; $12.9M total (Accel/General Catalyst Series A 2021 + ₹50Cr pre-Series B 2023) competing with Twin Health.
About
Breathe Well-being is a Gurugram, India-based digital therapeutics platform — backed by Y Combinator (W20) with $12.9 million in total funding including a ₹50 crore ($6 million) pre-Series B in 2023 and a $5.5 million Series A in August 2021 led by Accel with General Catalyst, 3one4 Capital, and Scott Shleifer — providing Indians with clinically validated digital programs for reversing and managing Type 2 diabetes, PCOD (polycystic ovarian disease), thyroid disorders, and hypertension through structured weight loss programs combining personalized nutrition coaching, behavioral change support, and continuous glucose monitoring. Founded in 2020 with a mission to help 1 million Indians reverse Type 2 diabetes by 2025, Breathe targets India's 150 million chronic lifestyle disease patients.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.